Literature DB >> 21255674

Biomarkers of genotoxicity and genomic instability in a non-human primate, Cebus libidinosus (Cebidae, Platyrrhini), exposed to nitroimidazole derivatives.

Marta Dolores Mudry1, Romari Alejandra Martinez, Mariela Nieves, Marta Ana Carballo.   

Abstract

The genotoxicity of two nitroimidazole derivatives, ornidazole (ONZ) and metronidazole (MTZ) in the peripheral blood lymphocytes of Cebus libidinosus (CLI) (Primates, Cebidae) was assessed. Endpoints measured included sister chromatid exchange (SCE) frequency, cell proliferation kinetics (CPK), replication index (RI), mitotic index (MI), and damage incidence in or near CLI heterochromatin regions. MI and SCE values following ONZ or MTZ treatments were significantly different (p<0.001) from control. SCE frequency per chromosome was not proportional to chromosome length. The chromosomes most affected for SCE were 1, 2, 4, 6, 11-13, 17, and 18, many of which possess interstitial or terminal heterochromatin. In the CLI genome, chromosomes 11 and 17 showed higher susceptibility to damage RI was the only biomarker that did not show statistically significant differences between control and treated cultures. C. libidinosus bands 11q1.4 and 11q1.5 may be hot-spots in the context of nitroimidazole exposure.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255674     DOI: 10.1016/j.mrgentox.2011.01.002

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  2 in total

1.  Association between Genomic Instability and Evolutionary Chromosomal Rearrangements in Neotropical Primates.

Authors:  Fiona Puntieri; Nancy B Andrioli; Mariela Nieves
Journal:  Genome Biol Evol       Date:  2018-07-01       Impact factor: 3.416

Review 2.  Advances in the Analysis of Veterinary Drug Residues in Food Matrices by Capillary Electrophoresis Techniques.

Authors:  Raffaella Colombo; Adele Papetti
Journal:  Molecules       Date:  2019-12-17       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.